摘要:
The present invention describes a series of novel therapeutically active compounds of formula (I), X-Y-Z that are useful for treating a disorder in a mammal.
摘要:
The present solution relates to a method comprising, as a key step, production of optically pure or optically enriched tapentadol of formula I, in which optically pure or optically enriched (2 R ,3 R )-amines of general formula V, wherein R stands for a phenylmethyl group, substituted or non-substituted in the benzene ring, e.g. benzyl or 4-methoxybenzyl, benzhydryl or trityl group, are hydrogenated on a metal catalyst and, if desired, the obtained tapentadol is converted by the action of pharmaceutically acceptable acids to respective salts, such as to hydrochloride.
摘要:
Provided is a process for the preparing l-phenyl-3-dimethylaminopropane derivatives of formula I, (The formula should be inserted here) and its pharmaceutically acceptable salts thereof via novel intermediates.
摘要:
Process for preparing 1-phenyl-3-dimethylaminopropane derivatives of formula (I), and pharmaceutically acceptable salts thereof from intermediate of formula (II) are provided, wherein R1 can be selected from -OR2, halo, -CH2OR2, -SR2, SOR2, SO2R2, -SO3H, -NO2, -NR2R2', - CONR2R2 ', and the like; R ' can be selected from hydrogen, alkyl, aryl, aralkyl, alkaryl, heteroaryl, and the like; or R2 and R2 ' can be same or different and can be selected from hydrogen, alkyl, aryl, aralkyl, heteroaryl,-OR3, - COR3, -PO3(R3R1) wherein R1 and R4 can be same or different and can be selected from alkyl, aryl, aralkyl, heteroaryl and the like.
摘要翻译:提供了制备式(I)的1-苯基-3-二甲基氨基丙烷衍生物及其药学上可接受的盐从式(II)中间体制备的方法,其中R 1可以选自-OR 2,卤素,-CH 2 OR 2,-SR 2,SOR 2 ,SO 2 R 2,-SO 3 H,-NO 2,-NR 2 R 2', - CONR 2 R 2'等; R'可以选自氢,烷基,芳基,芳烷基,烷芳基,杂芳基等; 或R 2和R 2'可以相同或不同,并且可以选自氢,烷基,芳基,芳烷基,杂芳基,-OR3,-CON3,-PO3(R3R1),其中R1和R4可以相同或不同,并且可以选自 烷基,芳基,芳烷基,杂芳基等。
摘要:
The present invention relates to processes for preparation of 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol of Formula I, which is a metabolite of tolterodine.
摘要:
Compounds of formula (I) or pharmaceutically acceptable salts thereof wherein Ar , Ar , R , R , n and X are as defined in the specificationas well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
摘要:
The present invention relates to a process for the preparation of tapentadol and analogs or compounds or stereoisomers of formula (I), Formula I wherein, A is aryl, heteroaryl, and cycloalkyl; R is H, OH, OR 1 , halogen, C 1 -C 12 alkyl, cycloalkyl, aryl or heteroaryl; R 1 is C 1 -C 12 alkyl, cycloalkyl, aryl or heteroaryl, wherein each of these groups may further be substituted with one or more substituent selected from H, OH, halogen, CN, NO 2 , C 1 -C 4 alkyl or phenyl. Further, the multi-step process involves no column chromatography purification until the very last step. This makes this process highly commercially viable and industrially useful.
摘要:
Described herein are compounds that are semicarbazide-sensitive amine oxidase (SSAO) inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating or preventing a liver disease or condition.
摘要:
A method for the preparation of tapentadol in the form of a base or its hydrogen chloride, which involves the preparation of a salt (III) from a mixture of diastereomers (II) by means of crystallization-induced asymmetric transformation (CIAT) through oxo-enol tautomeric equilibrium of covalently linked diastereomers, shifted towards the desired diastereomer without the use of chiral resolution with chiral carboxyl acids.